Wells Fargo Sees No Signs of a Turnaround at Valeant (VRX), Sees 2017 EPS at Risk
Tweet Send to a Friend
Wells Fargo analyst David Maris reiterated his Underperform rating on Valeant Pharmaceuticals (NYSE: VRX) ahead of Q2 results on August ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE